News

Scotland: £60m for genomic medicine
Enlarge image

FundingUK

Scotland: £60m for genomic medicine

29.08.2012 - A pioneering genetics research centre at the University of Edinburgh receives £60m (€75,6m) funding from the Medical Research Council (MRC).

The university has also received a £3.5m (€4,4m) award from the Wellcome Trust and Wolfson Foundation to help fund the building of a new systems medicine centre. The MRC funding will be used to fund research at Edinburgh's MRC Human Genetics Unit and the MRC Institute of Genetics and Medicine (IGMM) into a range of conditions, such as schizophrenia, cystic fibrosis, and genetic eye disorders, and to develop and test new therapies. IGMM is a partnership between the MRC, the University of Edinburgh's Centre for Molecular Medicine, and Cancer Research UK.

“This funding will help us to turn the potential of the genetic revolution into reality” said Institute director Nick Hastie in a video. He explained that most of the money would continue to fund ongoing programmes in the Human Genetics Unit, but that “ten to twenty percent, combined with money from the University of Edinburgh, will allow us to do exciting new science”. This would include recruiting top researchers, purchasing new equipment, developing a brand new PhD programme and helping the centre to integrate its research with the NHS. Professor Hastie said that the ‘big aim’ was to bring the results of research into clinical practice to aid the diagnosis and treatment of disease.

The £3.5m in funding from the Wellcome Trust and the Wolfson Foundation, awarded under the Wellcome-Wolfson Capital Awards programme, will support a new systems medicine building with the construction set to start in 2013 at Edinburgh's Western General Hospital. The five-story systems medicine building will total 2,700 meters squared, and will "create a physical and intellectual bridge between centres that make up the IGMM. In addition to research spaces, the facility will include spaces for computational biology, a seminar room, offices, and an "open design" to encourage research collaborations, according to IGMM. The remainder of the estimated £10.2m for the systems medicine facility will be provided by the University of Edinburgh and the MRC.

http://www.european-biotechnology-news.com/news/news/2012-03/scotland-pound60m-for-genomic-medicine.html

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

M&AIreland

08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.

BusinessIreland

07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.

BusinessSwitzerland

03.07.2015 Biotech giant Biogen is investing CHF1bn in a new pharmaceutical production plant in the Swiss town of Luterbach. Noted as one of the world’s oldest biotech firms, Biogen will create up to 400 jobs at the new plant.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • KAROLINSKA (S)12.95 SEK8.37%
  • IXICO (UK)35.50 GBP5.97%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • MEDIGENE (D)9.65 EUR-10.32%
  • SERODUS (N)3.08 NOK-8.88%
  • ZELTIA (E)3.69 EUR-8.44%

TOP

  • IXICO (UK)35.50 GBP57.8%
  • DBV TECHNOLOGIES (F)75.75 EUR43.9%
  • ADOCIA (F)88.67 EUR28.9%

FLOP

  • BIOTEST (D)25.26 EUR-64.3%
  • BIOTECH PHARMACON (N)9.44 NOK-47.6%
  • TRANSGENE (F)2.95 EUR-39.4%

TOP

  • ADOCIA (F)88.67 EUR532.9%
  • VERONA PHARMA (UK)4.88 GBP324.3%
  • FORMYCON (D)28.20 EUR305.8%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEOVACS (F)1.05 EUR-69.6%
  • BIOTEST (D)25.26 EUR-69.3%

No liability assumed, Date: 27.07.2015